CD8A and neoplasm: In a phase I clinical trial in patients with advanced solid tumors, an EP4 inhibitor significantly enhanced tumor infiltration of CD3+ and CD8+ T cells, while the levels of MDSCs in these patients were not reported (NCT02540291).